NOC · Q1 2026 Earnings
BullishNorthrop Grumman
Reported April 21, 2026
30-second summary
Q1 revenue of $9.88B (+4% YoY) beat the "low single digits" framing from January, FY26 guidance was reaffirmed across all four metrics, and management closed the B-21 production-rate acceleration agreement that had been deferred for three consecutive quarters — converting the largest open watch-list item into a positive resolution. The cautious counterweights: Q1 segment OM rate of 10.8% printed below the FY26 "low to mid 11%" framing and the 11.2% Q4 exit, Space Systems contracted 3% after Q4's +5% inflection print, and B-21 acceleration is still explicitly excluded from the reaffirmed FY26 guide — meaning the upside catalyst remains a 2027 event.
Headline numbers
EPS
Q1 FY2026
$6.14
Revenue
Q1 FY2026
$9.88B
+4.0% YoY
Free cash flow
Q1 FY2026
$-1.82B
Operating margin
Q1 FY2026
10.0%
Key financials
Q1 FY2026| Metric | Q1 FY2026 | YoY | Q4 FY2025 | QoQ |
|---|---|---|---|---|
| Revenue | $9.88B | +4.0% | $11.71B | -15.6% |
| EPS | $6.14 | — | $7.23 | -15.1% |
| Operating margin | 10.0% | — | 10.9% | -90bps |
| Free cash flow | $-1.82B | — | $3.23B | -156.4% |
Guidance
Company reaffirmed full-year FY2026 guidance across all major metrics (revenue, EPS, segment operating income, FCF, margin rate) while Q1 FY2026 beat low single-digit revenue guidance with 4% YoY growth.
Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.
Actuals vs prior guidance
| Metric | Period | Prior guide | Actual | Δ | Result |
|---|---|---|---|---|---|
| Revenue | Q1 FY2026 | Low single digits YoY growth | 9.881 billion | +4% actual YoY vs low single-digit guide; beat implied ceiling of ~2-3% | Beat |
New guidance
| Metric | Period | Guide | YoY |
|---|---|---|---|
| Segment Operating Margin Rate | Q1 FY2026 | 10.8% | — |
| Capital Expenditures | FY 2026 | $1.85 billion | — |
| Sequential Sales Growth | Q2 FY2026 | High single-digit | +5-13% YoY |
Reaffirmed unchanged this quarter: Revenue ($43.5 billion - $44.0 billion), EPS (non-GAAP / MTM-adjusted) ($27.40 - $27.90), Segment Operating Income ($4,850 million - $5,000 million), Free Cash Flow ($3,100 million - $3,500 million), Segment Operating Margin Rate (Low to mid 11%)
Segment KPIs
Q1 FY2026| Segment | Q1 FY2026 | YoY |
|---|---|---|
| Aeronautics Systems | $3.283B | +17.0% |
| Defense Systems | $1.899B | +5.0% |
| Mission Systems | $2.861B | +2.0% |
| Space Systems | $2.48B | -3.0% |
Other KPIs
Q1 FY2026| Segment | Q1 FY2026 |
|---|---|
| Net Awards | $9.8 billion |
| Total Backlog | $95.6 billion |
| Segment Operating Margin Rate | 10.8% |
| Aeronautics Systems Operating Margin | 9.3% |
| Defense Systems Operating Margin | 9.7% |
| Mission Systems Operating Margin | 15.1% |
| Space Systems Operating Margin | 9.5% |
| Organic Sales Growth | 5% |
Management tone
Narrative arc: Sentinel back on track → Generational tailwinds, broad raise → Margin discipline despite revenue retreat → Urgent capacity, but guide still excludes the upside → Capacity now enabling acceleration; weapons elevated to core pillar.
Capacity language completed its arc from "expanding" (Q2) to "tripling" (Q4) to "now enabling acceleration" (Q1). Three quarters ago management was telegraphing doubled SRM capacity. Two quarters ago that escalated to tripling. This quarter the framing flipped from build to harvest: "In the last two years, we've opened over 20 new facilities and added more than 2 million square feet of manufacturing space... we have agreed with our customers on plans to accelerate the Sentinel program, increase the rate at which we build the B-21, become a second source supplier of solid rocket motors on several programs, and ramp our rate of production on another handful of programs." The shift signals that the capacity CapEx of 2024–2025 is now translating to contracted rate increases — a meaningful de-risking of the speculative-CapEx critique that built through 2025.
Weapons reframed from supporting line to core growth pillar. Through 2025 munitions were discussed as a beneficiary of demand and capacity build, but were never quantified as a percentage of company sales. This quarter management put a number on it: "Our weapons business is nearing 10% of total company sales and is positioned to grow at a pace well above the company average." The shift signals that weapons is no longer a feeder to Defense Systems' narrative but a standalone growth thesis approaching the scale of B-21 (also nearing 10%) and matching missile defense (10%). For investors modeling the FY27 step-up, weapons just became a separately trackable line.
B-21 finally moved from "coming months" to deal-in-hand. Q2-25, Q3-25, and Q4-25 all said the deal was imminent and pushed the timeline. This quarter the language is past-tense: "This agreement demonstrates the strong operational requirements for the platform and confidence in our team to accelerate the delivery of this next-generation capability... Importantly, this agreement accelerates production for our customer, enhances the program's long-term economics, and creates the potential for a larger program of record." The Q&A confirmed no meaningful EAC change — offsetting increased production costs with later-phase profitability gains. The credibility hit from three consecutive "coming months" prints is repaired, but the upside is still excluded from the FY26 guide.
Sentinel went from long-cycle to near-term accelerant. A year ago Sentinel was a multi-decade modernization program with IFC pushed to 2033. This quarter management positioned it as a 2026 growth contributor: "We expect strong growth from Sentinel throughout the year as we ramp up on the new baseline, with the program already delivering double digit growth in the first quarter." The Q&A added Sentinel is 6–7% of revenue today with low double-digit growth and milestone B decision later this year. The shift signals milestone density in 2026–2027 that the FY26 guide does not fully capture.
Macro framing escalated from "generational" to "structured demand signals." Q2 framed European NATO commitments as a generational shift; Q3 maintained "unprecedented demand"; Q4 added "transforming Northrop Grumman." This quarter management introduced a new framing: "the administration is working closely with industry to provide clear, long-term demand signals through structured production frameworks." Combined with the $1.5T FY27 budget request (vs. $1.0T FY26 appropriated), management is signaling that the government-contractor relationship itself has shifted toward something more durable than annual appropriations — an unusually forward statement for a defense prime.
Recurring themes management leaned on this quarter:
Risks management surfaced:
Q&A highlights
Christine Levi · Morgan Stanley
How can Northrop Grumman achieve double-digit growth given mid-single-digit guidance, and what are the key bottlenecks? Additionally, how should investors think about Northrop's positioning on the FAXX contract with potential award in Q3 and upside to 2026 outlook?
Management outlined multiple levers for higher growth: bidding on new opportunities, winning at high competitive rates, accelerating missile component demand (especially solid rocket motors), converting international pipeline to sales, and removing supply chain bottlenecks. On FAXX, Northrop is confident in its ability to deliver, has suppliers prepared, and expects upside to sales and earnings if selected in Q3. The company would make it a top priority.
Sheila Kayalu · Jefferies
What are the revenue and earnings profiles for the four key growth drivers: B-21, Sentinel, missiles, and missile defense? When will these programs inflect?
Sentinel is 6-7% of revenue, growing low double-digits with production long-lead inflection later this decade. B-21 nearing 10% of revenue and expected to exceed 10% over next several years. Weapons (munitions and prime integrator position) at ~10% expected to be one of fastest growers. Missile defense at 10% of revenue. All four programs have margin upside as they move from development into production phases.
Robert Stallard · Vertical Research
What is the timeline for B-21 capex spending and production flow, and what protections exist against B-2 style curtailment?
Management expects $200 million capex this year with majority of capital expenditure in 2027-2029 timeframe, largely completed this decade. Additional capacity will generate meaningful revenue increase over program life, with revenue profile following production facility completion. B-21 is protected by committed quantity on contract, and Air Force is considering increasing program of record. Strong administration support for capability driven by triad modernization and national defense strategy.
Scott Mikus · Milius Research
Are European customers becoming wary of ordering from U.S. companies due to uncertainty about delivery timelines given competing U.S. demand priorities?
European demand remains robust despite sensitivities around delivery timelines and preference for local suppliers. Northrop is investing in capacity (20 facilities opened in last 24 months, 2+ million sq ft manufacturing space) and can meet both U.S. and European commitments without trading off one for the other. Space business has least international pipeline but expected to grow significantly.
Seth Seifman · JP Morgan
On the B-21 production agreement, what portion of profitability improvements will come from LRIP unit reversals versus NTE units? Also, how should investors think about offsetting $2.5 billion capex investment over 2027-2028 against the 2028 cash flow target?
The production agreement improved overall program economics with no meaningful EAC change—offsetting increased production costs with later-phase profitability gains. No specific guidance on LRIP reversal timing; profitability improvements expected from manufacturing capability and production rate improvements. Company did not provide 2027-2028 cash flow guidance due to large awards outstanding and capex timing, but emphasized strong cash generation power of the business will continue.
Answers to last quarter's watch list
What to watch into next quarter
FAXX award decision in Q3. Management characterized FAXX as a top priority with suppliers prepared and explicit upside to 2026 sales and earnings. A win is a discrete catalyst that would force a mid-year guide raise; a loss removes the cleanest 2026 upside lever and leaves NOC's near-term growth dependent entirely on backlog conversion. Watch for any guide commentary at Q2 print that pre-positions for either outcome.
Q2 segment OM rate recovery toward 11%+. Q1 at 10.8% needs to trend up to validate the "low to mid 11%" FY guide. If Q2 prints flat or down — call it sub-11% again — the FY segment income guide of $4,850–5,000M comes under pressure and the "margins improve over the course of the year" framing loses credibility.
Mission Systems growth re-acceleration. Q1 +2% was a sharp deceleration from Q3-25 +10% and Q4-25 +10%. Without transcript-level explanation, this is the cleanest negative data point in the print. Watch whether Q2 recovers to mid-to-high-single-digits — if it stays at low-single-digits, the FY broad-based growth thesis carries less weight.
Space Systems back to positive growth. Q4-25 inflected to +5%; Q1-26 fell back to -3%. The "all four segments growing" line from January did not hold. A Q2 return to flat or positive validates the program wind-down lap as complete; a third negative print forces a rethink on Golden Dome contribution timing.
GEN63 XL EAC stability. The $71M Q1 charge is the first crack in the speculative-SRM-CapEx thesis. Watch whether Q2 carries any additional unfavorable EAC adjustments, or whether management quantifies a 2026 volume floor that protects the program economics.
Book-to-bill recovery above 1.0x. Q1's 0.99x is the first sub-1x quarter since Q2-25 and the headline backlog ticked down $0.1B QoQ. A second sub-1x quarter while management is signaling "structured production frameworks" from DoD would be a meaningful inconsistency. Watch for a 1.1x+ Q2 print to restore the backlog growth trajectory.
Capital return posture at Q2 print. Buybacks were suspended beyond January 2026 and the May dividend decision was deferred. Whether NOC reinstates buybacks, raises the dividend, or holds both back will signal management's read on whether the 2027–2028 CapEx and B-21 investment cycle is fully self-funded.
Sources
- NOC Q1 2026 earnings release (SEC filing): https://www.sec.gov/Archives/edgar/data/1133421/000113342126000015/noc-03312026xearningsrelea.htm
- NOC Q1 2026 earnings call commentary (as captured in tone and Q&A extraction)
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.